SUTRO BIOPHARMA, INC. (STRO) Operating Margin
- Operating margin · 12 months: Value -319.57%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -319.57% | Operating income / revenue. Period ending 2026-06-30. $-146.05M ÷ $45.70M × 100 ≈ -319.57% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -146.05M USD | Operating Income (Loss) |
| Revenue | 45.70M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 144.74M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-146.05M | $45.70M | (m) | $144.74M | (m) | -319.57% |
| 2026-03-31 | $-119.51M | $99.61M | (m) | $151.37M | (m) | -119.98% |
| 2025-12-31 | $-158.37M | $102.48M | (m) | $166.42M | (m) | -154.53% |
| 2025-09-30 | $-185.58M | $105.65M | (m) | $200.81M | (m) | -175.66% |
| 2025-06-30 | $-205.04M | $104.47M | (m) | $223.07M | (m) | -196.26% |
| 2025-03-31 | $-250.38M | $66.43M | (m) | $246.76M | (m) | -376.88% |
| 2024-12-31 | $-238.45M | $62.04M | (m) | $252.04M | (m) | -384.34% |
| 2024-09-30 | $-130.04M | $160.96M | (m) | $234.77M | (m) | -80.79% |
| 2024-06-30 | $-106.14M | $169.36M | (m) | $218.33M | (m) | -62.67% |
| 2024-03-31 | $-103.63M | $154.06M | (m) | $197.90M | (m) | -67.27% |
| 2023-12-31 | $-89.28M | $153.73M | (m) | $180.43M | (m) | -58.07% |
| 2023-09-30 | $-181.65M | $48.64M | (m) | $169.79M | (m) | -373.45% |
| 2023-06-30 | $-158.85M | $56.87M | (m) | $155.84M | (m) | -279.34% |
| 2023-03-31 | $-132.05M | $74.55M | (m) | $146.58M | (m) | -177.13% |
| 2022-12-31 | $-128.94M | $67.77M | (m) | $137.17M | (m) | -190.26% |
| 2022-09-30 | $-114.76M | $69.79M | (m) | $123.96M | (m) | -164.42% |
| 2022-06-30 | $-128.22M | $53.16M | (m) | $118.85M | (m) | -241.18% |
| 2022-03-31 | $-118.65M | $53.12M | (m) | $111.83M | (m) | -223.37% |
| 2021-12-31 | $-98.52M | $61.88M | (m) | $104.40M | (m) | -159.22% |
| 2021-09-30 | $-88.33M | $59.50M | (m) | $97.21M | (m) | -148.45% |
| 2021-06-30 | $-64.27M | $68.81M | (m) | $89.97M | (m) | -93.41% |
| 2021-03-31 | $-70.89M | $50.23M | (m) | $81.90M | (m) | -141.12% |
| 2020-12-31 | $-71.06M | $42.72M | (m) | $76.96M | (m) | -166.32% |
| 2020-09-30 | $-61.00M | $45.75M | (m) | $71.61M | (m) | -133.33% |
| 2020-06-30 | $-63.11M | $40.20M | (m) | $69.15M | (m) | -156.99% |
| 2020-03-31 | $-60.38M | $41.26M | (m) | $68.05M | (m) | -146.35% |
| 2019-12-31 | $-55.47M | $42.74M | (m) | $65.61M | (m) | -129.79% |
| 2019-09-30 | $-43.96M | $50.52M | (m) | $63.01M | (m) | -87.02% |
| 2019-06-30 | $-41.38M | $46.08M | (m) | $58.75M | (m) | -89.81% |
| 2019-03-31 | $-39.79M | $41.26M | (m) | $56.36M | (m) | -96.44% |
| 2018-12-31 | $-37.22M | $38.42M | (m) | $54.26M | (m) | -96.89% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $33.04M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $42.69M | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-19.27M | $51.74M | (m) | $54.64M | (m) | -37.25% |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $1.36M | $59.73M | (m) | $43.55M | (m) | 2.28% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |